A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema

To join this study, children must be between 6 and under 12 years old and have moderate-to-severe eczema that has been diagnosed for at least a year. Their eczema must also cover a certain amount of their body, be quite red and thick, and be causing them a fair bit of itching.

They should have tried usual skin treatments like creams and ointments for at least four weeks, but these treatments haven't worked well enough for their eczema to improve. They should also weigh at least 15 kg (about 2 stone 5 pounds).

Children cannot take part if they have certain other medical conditions, especially recent skin infections or other serious infections that needed hospital treatment. The study also cannot include children with certain mental health concerns or ongoing problems that might make it unsafe to take part.

If your child joins the study, they will either receive the new medicine, abrocitinib, or a 'pretend' medicine (placebo) for 16 weeks. They won't know which one they are getting, and neither will the study team, to make sure the results are fair. The study will last for about 24 weeks in total.

During this time, your child will need to visit the clinic regularly. At other times, the study doctor or nurse might call you to check how your child is doing. Your child will also use a special electronic diary, like a small mobile phone, to answer questions about their eczema and to remind them to take their medicine every day. They might also wear a special wrist device, similar to a children's watch, which helps the researchers understand when they are scratching their skin.

Throughout the study, the team will do various health checks, including physical examinations, checking their height, weight, temperature, blood pressure, and heart rate, and taking blood samples for lab tests. This is all to keep an eye on their health and see how the medicine is affecting them.